Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126754011 | 12675401 | 1 | I | 20160614 | 20160817 | 20160823 | 20160823 | EXP | CH-SM-2016-06512 | CH-ROCHE-1816038 | ROCHE | 65.40 | YR | M | Y | 81.00000 | KG | 20160823 | MD | CH | CH |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126754011 | 12675401 | 1 | PS | XELODA | CAPECITABINE | 1 | Oral | UNKNOWN IF SECOND CYCLE WILL BE ADMINISTERED | U | 20896 | 2000 | MG | TABLET | BID | |||||
| 126754011 | 12675401 | 2 | SS | TEMODAL | TEMOZOLOMIDE | 1 | Oral | U | 0 | 400 | MG | CAPSULE | QD | ||||||
| 126754011 | 12675401 | 3 | SS | ISCADOR | VISCUM ALBUM FRUITING TOP | 1 | Subcutaneous | Y | 0 | SOLUTION FOR INJECTION | |||||||||
| 126754011 | 12675401 | 4 | SS | NAPROXEN. | NAPROXEN | 1 | Oral | Y | 17581 | 500 | MG | TABLET | |||||||
| 126754011 | 12675401 | 5 | SS | NOVALGIN (SWITZERLAND) | DIPYRONE | 1 | Oral | Y | 0 | 500 | MG | FILM-COATED TABLET | |||||||
| 126754011 | 12675401 | 6 | C | CREON | PANCRELIPASE AMYLASEPANCRELIPASE LIPASEPANCRELIPASE PROTEASE | 1 | Oral | 0 | 25000 | IU | TID | ||||||||
| 126754011 | 12675401 | 7 | C | PANTOPRAZOL | PANTOPRAZOLE SODIUM | 1 | Oral | 0 | 40 | MG | GASTRO-RESISTANT COATED TABLET | QD | |||||||
| 126754011 | 12675401 | 8 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | Y | 0 | 4 | DF | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QD | ||||||
| 126754011 | 12675401 | 9 | C | DAFALGAN | ACETAMINOPHEN | 1 | Oral | 0 | 1 | G |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126754011 | 12675401 | 1 | Pancreatic neuroendocrine tumour |
| 126754011 | 12675401 | 2 | Pancreatic neuroendocrine tumour |
| 126754011 | 12675401 | 3 | Pancreatic neuroendocrine tumour |
| 126754011 | 12675401 | 4 | Tumour associated fever |
| 126754011 | 12675401 | 5 | Pain |
| 126754011 | 12675401 | 8 | Insulin-requiring type 2 diabetes mellitus |
| 126754011 | 12675401 | 9 | Pain |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126754011 | 12675401 | HO |
| 126754011 | 12675401 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126754011 | 12675401 | Agranulocytosis | |
| 126754011 | 12675401 | Leukopenia | |
| 126754011 | 12675401 | Neutropenia | |
| 126754011 | 12675401 | Off label use | |
| 126754011 | 12675401 | Petechiae | |
| 126754011 | 12675401 | Pruritus | |
| 126754011 | 12675401 | Purpura | |
| 126754011 | 12675401 | Rash generalised | |
| 126754011 | 12675401 | Thrombocytopenia | |
| 126754011 | 12675401 | Vasculitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126754011 | 12675401 | 1 | 20160614 | 20160628 | 0 | |
| 126754011 | 12675401 | 2 | 20160623 | 20160628 | 0 | |
| 126754011 | 12675401 | 3 | 20160625 | 20160627 | 0 | |
| 126754011 | 12675401 | 4 | 20160705 | 20160714 | 0 | |
| 126754011 | 12675401 | 5 | 201604 | 20160704 | 0 | |
| 126754011 | 12675401 | 8 | 201607 | 0 |